Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
62.12
+0.44 (+0.71%)
Streaming Delayed Price
Updated: 3:55 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
March 06, 2023
From
Incyte
Via
Business Wire
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns
March 06, 2023
Via
Benzinga
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
March 03, 2023
From
Incyte
Via
Business Wire
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
February 24, 2023
From
Incyte Corporation
Via
Business Wire
Incyte's Return On Capital Employed Overview
February 08, 2023
Via
Benzinga
Analyst Ratings for Incyte
February 08, 2023
Via
Benzinga
Incyte to Present at Upcoming Investor Conference
February 16, 2023
From
Incyte
Via
Business Wire
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
February 10, 2023
From
Incyte
Via
Business Wire
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
February 07, 2023
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled.
Via
Investor's Business Daily
Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst
February 07, 2023
Via
Benzinga
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
February 07, 2023
From
Incyte
Via
Business Wire
Earnings Outlook For Incyte
February 06, 2023
Via
Benzinga
2 Steady Stocks to Buy in a Recession
February 03, 2023
Both companies are performing better than the broader market over the past year.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
January 31, 2023
Via
Benzinga
Incyte to Present at Upcoming Investor Conference
January 24, 2023
From
Incyte
Via
Business Wire
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
January 19, 2023
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before.
Via
Investor's Business Daily
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
Golden Cross Appears Before Incyte Investors
December 09, 2022
Via
Benzinga
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
January 18, 2023
From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock...
Via
Talk Markets
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
January 17, 2023
From
Incyte
Via
Business Wire
Why These 7 Healthcare Stocks Could Soar in 2023
January 02, 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.
Via
InvestorPlace
Week In Review: Ten Biggest 2022 China Biopharma Deals Worth $21.5 Billion
December 31, 2022
China Biopharma deal activity in 2022 was certainly slower than the previous year, but the ten largest deals, many of them booked in the second half of the year, totaled a decent $21.5 billion by...
Via
Talk Markets
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
December 29, 2022
These two biotechs are flying high right now.
Via
The Motley Fool
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.
Via
InvestorPlace
Cramer Says He's 'Always Liked' This Drug Company
December 16, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Oshkosh Corporation (NYSE: OSK) is a "slow grower.
Via
Benzinga
Incyte to Present at Upcoming Investor Conferences
December 15, 2022
From
Incyte
Via
Business Wire
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 13, 2022
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX<
Via
Benzinga
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
December 11, 2022
From
Incyte
Via
Business Wire
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
December 10, 2022
From
Incyte
Via
Business Wire
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
December 02, 2022
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.